Physician profile
Askin Uysal
NPI 1568441210
$4,350.98
in general payments reported to CMS, 2019-2025
9 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2021: $140 · 2022: $471 · 2023: $392 · 2024: $1,600 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Travel and Lodging: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.18 |
| Travel and Lodging | $469.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,740.21 | 2021-2025 | Impella |
| Boston Scientific Corporation | $1,145.45 | 2019 | |
| Getinge USA Sales, LLC | $613.27 | 2022-2024 | Vasoview Hemopro 2 |
| Abbott Laboratories | $321.76 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $212.75 | 2024 | Mc3 Nautilus(Tm) Ecmo Oxygenator |
| Becton, Dickinson and Company | $183.67 | 2025 | Hemosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.67 | 2023 | |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Livanova USA, INC. | $15.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Askin Uysal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.